HR and breast cancer: In breast cancer, data from the latest MONARCH-3 study showed that at a median follow-up time of 8.1 years, treatment with Abemaciclib in combination with an nonsteroidal aromatase inhibitor (NSAI) numerically prolonged Overall Survival (OS) compared to NSAI therapy alone in patients with HR+, HER2- advanced breast cancer, however, unfortunately, the difference did not reach statistical significance (P=0.0664) (47).